Spectral Medical (TSE:EDT) has released an update. Spectral Medical has successfully enrolled 135 patients in its Phase 3 Tigris trial, which ...

Dr. John Kellum, Chief Medical Officer of Spectral, noted, “Despite a lower enrollment rate for October we continue to see strong performance across trial sites for screening. Our sites are eager to ...

PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s Endotoxin Activity Assay (EAA™), the only ...

The OSCAR study is a Prospective Single-Arm Feasibility Trial to evaluate the initial safety and signals of efficacy by determining the ability of the ONCObind Procedure Hemoperfusion Filter to ...